Holen Sie sich die Stockscreener-App
60.49
2.09%
1.24
Handel nachbörslich:
60.25
-0.24
-0.40%
Schlusskurs vom Vortag:
$59.25
Offen:
$59.02
24-Stunden-Volumen:
992.95K
Relative Volume:
0.72
Marktkapitalisierung:
$7.08B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
20.03
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+2.89%
1M Leistung:
-6.71%
6M Leistung:
+22.82%
1J Leistung:
+57.28%
1-Tages-Spanne:
$58.49
$60.90
1-Wochen-Bereich:
$56.47
$60.90
52-Wochen-Spanne:
$37.97
$66.00
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
60.49 | 7.08B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme shares surge 53% following InvestingPro’s November fair value call By Investing.com - Investing.com UK
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief - MSN
H.C. Wainwright maintains Buy on Halozyme stock, $72 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Halozyme stock, $72 target - Investing.com Australia
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter
Halozyme sues Merck over alleged patent infringement By Investing.com - Investing.com South Africa
Halozyme sues Merck, alleging injectable Keytruda will infringe its patents - Endpoints News
Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda - Bloomberg.com
Halozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent Infringement - GuruFocus
Merck stock flat despite Halozyme patent suit (MRK:NYSE) - Seeking Alpha
Halozyme Files Patent Infringement Lawsuit Against Merck - Nasdaq
Halozyme sues Merck over alleged patent infringement - Investing.com
Halozyme (HALO) Sues Merck Over Keytruda's Subcutaneous Patent Infringement | HALO Stock News - GuruFocus
Halozyme Therapeutics Sues Merck Over Alleged Patent Infringement - marketscreener.com
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation | HALO Stock News - GuruFocus
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - marketscreener.com
Halozyme Challenges Merck in Patent Battle Over Breakthrough Subcutaneous Keytruda Technology - Stock Titan
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com
Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.
Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow
Major EU Approval: Revolutionary Subcutaneous Multiple Myeloma Treatment Gets Green Light - Stock Titan
Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener
Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener
Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):